Insider Cluster (4 insiders) ·Filed Aug 26, 2026

OCUL

OCULAR THERAPEUTIX, INC
NEUTRAL
Impact 3/10
Horizonimmediate Processed1mo ago
Insider cluster: 4 insiders, $0.3M total
Actionable Insight • Neutral

Insider sales are routine and immaterial relative to market cap. No bearish signal — monitor for any upcoming material corporate events (earnings, pipeline updates) that could provide context, but this cluster alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
OCUL ▼ -9.24% at T+20d
NEUTRAL call ✗ call lost -9.24% · α vs SPY -8.73% · entry $10.82 → $9.82
Next anchor: T+60d in 7w
Latest observation: T+24 -35.32% FF3 residual α
Entry anchored
Aug 26, 2026
via day open
T+1d
-4.25%
call -4.25% · α -4.02%
$10.36
settled 5w ago
T+5d
-1.66%
call -1.66% · α -1.93%
$10.64
settled 4w ago
T+20d
-9.24%
call -9.24% · α -8.73%
$9.82
settled 8d ago
T+60d
—
call — · α —
—
in 7w

Price Chart

Loading chart...

Executive Summary

Four OCUL insiders, including the Chief Scientific Officer and Chief Strategy Officer, sold a total of $322K in open-market sales on August 24, 2026. The cluster is dominated by Dugel Pravin's $233K sale, but the total value is only ~0.013% of the $2.4B market cap, making it a trivial, routine event. A $0 gift of 50K shares by Dugel Pravin on the same day is a non-cash event with no economic signal. Per the asymmetric calibration, insider sales are weak predictors, and this cluster's small size relative to market cap does not warrant a bearish read-through.

Key Financial Metrics

Direction
selling
Total Value
$322.0K
Insiders
4

Key Facts

  • Four OCUL insiders sold $322K total in open-market sales on Aug 24, 2026, representing ~0.013% of market cap.
  • Dugel Pravin also gifted 50,092 shares ($0 value) on Aug 25, a non-cash event.
  • Sales are small in absolute and relative terms — no material signal from this cluster.
  • The cluster is not amplified by any cross-filing context; all cross-filing amplifiers are generic and not triggered by actual filings.

Financial Impact

Total insider sales of $322K, or ~0.013% of $2.4B market cap — trivial.

dilution

Risk Factors

  • No material risk identified from this insider activity; sales are too small to indicate informed selling.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-OCUL-1787781663126
14 reports for OCUL
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+20▲ +24.88%Aug 3, 2026
Filters
Rows
Reports for OCUL — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$10.90 $7.67▼ −29.63%▼ −29.30%$6.96 (−36.15%)
Aug 26, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$10.82 $9.82▼ −9.24%▼ −8.73%$6.96 (−35.67%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 7/10
$8.40 $10.49▲ +24.88%▲ +23.64%$6.96 (−17.14%)
Jun 17, 2026
15w ago
Press Release
BULLISH ★ 6/10
$9.64 $9.17▼ −4.93%▼ −6.24%$6.96 (−27.80%)
Jun 12, 2026
16w ago
8-K
NEUTRAL ★ 3/10
$8.99 $9.88▲ +9.90%▲ +10.65%$6.96 (−22.58%)
Jun 4, 2026
17w ago
Press Release
BULLISH ★ 7/10
$8.80 $9.64▲ +9.55%▲ +10.92%$6.96 (−20.91%)
May 28, 2026
18w ago
Insider Cluster
NEUTRAL ★ 3/10
$9.01 $9.90▲ +9.88%▲ +11.67%$6.96 (−22.75%)
May 5, 2026
21w ago
8-K
NEUTRAL ★ 5/10
$9.71 $8.31▼ −14.42%▼ −19.37%$6.96 (−28.32%)
May 5, 2026
21w ago
Press Release
MIXED ★ 6/10
$9.71 $8.31▼ −14.42%▼ −19.37%$6.96 (−28.32%)
Apr 30, 2026
22w ago
DEFA14A
NEUTRAL ★ 3/10
$9.43 $8.93▼ −5.30%▼ −10.57%$6.96 (−26.19%)
Showing 10 of 14

US Market Status

Market Closed — Opens Mon (65h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 26, 2026